首页 | 本学科首页   官方微博 | 高级检索  
     


Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study
Authors:Johanna Bendell  Sunil Sharma  Manish R. Patel  Kevin S. Windsor  Zev A. Wainberg  Michael Gordon  Jorge Chaves  Jordan Berlin  Carrie Baker Brachmann  Marianna Zavodovskaya  JieJane Liu  Dung Thai  Pankaj Bhargava  Manish A. Shah  Saad A. Khan  Alexander Starodub
Affiliation:1. Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA;2. Translational Genomics Research Institute, Phoenix, Arizona, USA;3. Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida, USA;4. Alabama Oncology, Birmingham, Alabama, USA;5. Department of Medicine, Division of Hematology Oncology, University of California Los Angeles School of Medicine, Santa Monica, California, USA;6. HonorHealth Research Institute, Scottsdale, Arizona, USA;7. Northwest Medical Specialties, PLLC, Tacoma, Washington, USA;8. Vanderbilt University Medical Center, Nashville, Tennessee, USA;9. Gilead Sciences, Inc, Foster City, California, USA;10. Weill Cornell Medicine, New York, New York, USA;11. Stanford University Medical Center, Stanford, California, USA;12. Riverside Peninsula Cancer Institute, Riverside Cancer Care Center, Newport News, Virginia, USA
Abstract:
Keywords:Andecaliximab  GS-5745  Matrix metalloproteinase 9  Pancreatic adenocarcinoma
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号